Drug General Information
Drug ID
D01CGV
Former ID
DIB016697
Drug Name
LY-2599506
Synonyms
PSN-010
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 2 [522877]
Company
Prosidion Ltd
Structure
Download
2D MOL

3D MOL

Target and Pathway
Target(s) Glucokinase Target Info Inhibitor [551195]
KEGG Pathway Glycolysis / Gluconeogenesis
Galactose metabolism
Starch and sucrose metabolism
Amino sugar and nucleotide sugar metabolism
Butirosin and neomycin biosynthesis
Metabolic pathways
Biosynthesis of antibiotics
Carbon metabolism
Insulin signaling pathway
Insulin secretion
Prolactin signaling pathway
Glucagon signaling pathway
Type II diabetes mellitus
Maturity onset diabetes of the young
Central carbon metabolism in cancer
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
HIF-1-alpha transcription factor network
PathWhiz Pathway Nucleotide Sugars Metabolism
Starch and Sucrose Metabolism
Galactose Metabolism
Trehalose Degradation
Reactome Regulation of gene expression in beta cells
Glucose transport
Glycolysis
WikiPathways SIDS Susceptibility Pathways
Glycolysis and Gluconeogenesis
MAPK Signaling Pathway
Regulation of beta-cell development
Metabolism of carbohydrates
Hexose transport
References
Ref 522877ClinicalTrials.gov (NCT01024244) A Study of LY2599506 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 551195This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.